Business
Aardvark Therapeutics Announces Leadership Appointments
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun’s role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. T
About this update from Aardvark Therapeutics, Inc.
[{"type":"image","alt":"Aardvark Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aardvark Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_2n1g9xWdfu1GQlbvtkO7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101","width":300,"height":63}},"lazy":false},{"type":"text","content":"SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun’s role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026.","length":553,"tagName":"p"},{"type":"text","content":"“These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the treatment of hyperphagia associated with Prader-Willi Syndrome and continue Phase 2 development of ARD-201 for obesity and obesity-related conditions,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “I am thrilled to welcome Derrick to the Aardvark team and look forward to his leadership and expertise in shaping our company’s next phase of growth. In addition, Nelson’s demonstrated strong leadership and operational expertise gives us confidence as he moves into his expanded role. Both appointments will be critical in helping us unlock meaningful value for our stockholders as well as the patients and clinicians that we serve.”","length":798,"tagName":"p"},{"type":"text","content":"In Mr. Li’s new role, he will lead Aardvark's business development strategy and execution with responsibility for financing, licensing, partnership strategy and corporate development initiatives.","length":199,"tagName":"p"},{"type":"text","content":"“I am excited to work with an experienced, dynamic and patient-focused group of individuals at such a defini...